Immuneering Pulls Cash Runway In To Late 2028 As It Enlarges Pancreatic Cancer Trial

The drug developer says faster, bigger Phase 3 enrollment shortens its cash runway from 2029 to the fourth quarter of 2028.

Share
Immuneering Pulls Cash Runway In To Late 2028 As It Enlarges Pancreatic Cancer Trial

Immuneering, which develops oral cancer drugs, now says its cash will last into the fourth quarter of 2028, a year-ish earlier than the 2029 runway it guided to before. The company said Thursday that a bigger, faster Phase 3 pancreatic cancer trial and other spending drove the change.

Three costs behind the shorter runway

The company's quarterly report ties the update to a longer-than-planned Phase 1/2a trial of atebimetinib in advanced solid tumors, a planned increase and acceleration of enrollment in its Phase 3 MAPKeeper 301 trial, and commercial readiness activities. Its risk factors now say it shortened its runway guidance in October 2026. The prior quarter's report had pointed to 2029.

In October the company raised the MAPKeeper 301 enrollment target to about 570 patients from 510, saying enrollment was ahead of schedule. It still expects topline data in mid-2028, with potential to come sooner.

CEO Ben Zeskind said in the earnings release that the 17.3-month median overall survival reported at ASCO is "unprecedented among agents targeting this pathway."

Cash down to $166.1 million

Cash, cash equivalents and marketable securities fell to $166.1 million at September 30, 2026, from $182.7 million at June 30. The company's net loss for the third quarter was $24.2 million, or $0.37 per share, against $15.0 million a year earlier.

Research and development expense reached $20.7 million, versus $10.9 million in the year-earlier quarter. Spending on atebimetinib was $13.6 million against $5.1 million, and $8.5 million of the direct cost increase came from running MAPKeeper 301. Headcount reached 65 full-time employees at September 30, from 57 at June 30.

A drug company with no product to sell

Immuneering describes itself as a late-stage clinical oncology company building Deep Cyclic Inhibitors, drugs meant to disrupt cancer-driving signaling in cycles. Lead candidate atebimetinib is a once-daily pill targeting a protein called MEK. The company has no approved products and no product revenue.

It says it must raise more capital to fund operations past the runway date, which could dilute holders. Most of its current cash came from September 2025 financing, including a public offering of 18,959,914 shares at $9.23 each that netted $164.1 million. Its market value was $258 million at Thursday's report time.

Updated Phase 2 atebimetinib data in 55 patients is due in the first half of 2027, and MAPKeeper 301 topline results are still targeted for mid-2028.

Sources

More on Immuneering

All Immuneering (IMRX) coverage →